Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 11/20 | 0.79 |
| ▸ | EDNRB | P24530 | 9/20 | 0.79 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.60 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7329161 | 0.91 | EDNRA (0.69) | EDNRAEDNRBAGTR1 | |
| SCHEMBL7340962 | 0.91 | EDNRA (0.66) | EDNRAEDNRBAGTR1 | |
| SCHEMBL8124977 | 0.89 | EDNRA (0.81) | EDNRAEDNRBAGTR1AGTR2 | |
| SCHEMBL8903408 | 0.89 | EDNRA (0.81) | EDNRAEDNRBAGTR1AGTR2 | |
| SCHEMBL7332944 | 0.88 | EDNRA (0.88) | EDNRAEDNRBAGTR1AGTR2 | |
| SCHEMBL7333006 | 0.88 | EDNRA (0.79) | EDNRAEDNRBAGTR1AGTR2 | |
| L-754142 SCHEMBL4193035 | 0.88 | EDNRA (1.00) | EDNRAEDNRBAGTR1AGTR2 | |
| L-754142 SCHEMBL29551244 | 0.88 | EDNRA (1.00) | EDNRAEDNRBAGTR1AGTR2 | |
| SCHEMBL8905309 | 0.88 | EDNRA (0.78) | EDNRAEDNRBAGTR1AGTR2 | |
| SCHEMBL8904132 | 0.88 | EDNRA (0.78) | EDNRAEDNRBAGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0617001-B1 | Phenoxyphenylacetic acid derivatives | MERCK & CO INC (US) | 2000-01-26 | — | — | EP | claimed |
| WO-1996009818-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF EMESIS | MERCK & CO., INC. (US) | 1996-04-04 | — | — | WO | claimed |
| US-10828368-B2 | Therapeutic treatments using centhaquin | MIDWESTERN UNIVERSITY (US) | 2020-11-10 | — | — | US | disclosed |
| US-20180085461-A1 | Novel Therapeutic Treatments Using Centhaquin | MIDWESTERN UNIVERISTY | 2018-03-29 | — | — | US | disclosed |
| US-20180085461-A1 | Novel Therapeutic Treatments Using Centhaquin | MIDWESTERN UNIVERISTY | 2018-03-29 | — | — | US | disclosed |
| EP-2424530-B1 | METHOD AND COMPOSITION FOR TREATING DIABETIC KETOACIDOSIS | UNIV MIDWESTERN (US) | 2015-12-16 | — | — | EP | disclosed |
| US-8980874-B2 | Method and composition for treating diabetic ketoacidosis | MIDWESTERN UNIVERSITY (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980874-B2 | Method and composition for treating diabetic ketoacidosis | MIDWESTERN UNIVERSITY (US) | 2015-03-17 | — | — | US | disclosed |
| US-20130225531-A1 | METHOD AND COMPOSITION FOR TREATING ALZHEIMER'S DISEASE AND DEMENTIAS OF VASCULAR ORIGIN | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225531-A1 | METHOD AND COMPOSITION FOR TREATING ALZHEIMER'S DISEASE AND DEMENTIAS OF VASCULAR ORIGIN | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-08-29 | — | — | US | disclosed |
| US-8410148-B2 | Method and composition for potentiating an opiate analgesic | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-04-02 | — | — | US | disclosed |
| US-7351692-B2 | Method and composition for potentiating the antipyretic action of a nonopioid analgesic | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2008-04-01 | — | — | US | disclosed |
| EP-0617001-B1 | Phenoxyphenylacetic acid derivatives | MERCK & CO INC (US) | 2000-01-26 | — | — | EP | disclosed |
| US-5767310-A | Phenoxyphenylacetic acid derivatives | MERCK & CO., INC. (US) | 1998-06-16 | — | — | US | disclosed |
| US-5668176-A | ENDOTHELIN ANTAGONIST | MERCK & CO. INC. (US) | 1997-09-16 | — | — | US | disclosed |
| US-5565485-A | TREATING CARDIOVASCULAR DISORDERS | MERCK & CO., INC. (US) | 1996-10-15 | — | — | US | disclosed |
| WO-1996009818-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF EMESIS | MERCK & CO., INC. (US) | 1996-04-04 | — | — | WO | disclosed |
| WO-1996004905-A1 | PHENOXYPHENYLACETIC ACID DERIVATIVES | MERCK & CO., INC. (US) | 1996-02-22 | — | — | WO | disclosed |
| WO-1994021590-A1 | PHENOXYPHENYLACETIC ACID DERIVATIVES | MERCK & CO., INC. (US) | 1994-09-29 | — | — | WO | disclosed |
| EP-0617001-A1 | Phenoxyphenylacetic acid derivatives | MERCK & CO. INC. (US) | 1994-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10828368-B2 | Therapeutic treatments using centhaquin | ADRA2A, ADRB3, HSPH1 | EDNRA 429/4885EDNRB 502/4885AGTR1 207/4885 |
| US-20130225531-A1 | METHOD AND COMPOSITION FOR TREATING ALZHEIMER'S DISEASE AND DEMENTIAS OF VASCULAR ORIGIN | PSEN1, PSEN2, CHAT | EDNRA 11/4885EDNRB 7/4885AGTR1 235/4885 |
| US-20180085461-A1 | Novel Therapeutic Treatments Using Centhaquin | ADRB3, ADRA2A, ADRB2 | EDNRA 141/4885EDNRB 148/4885AGTR1 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.